Upper gastrointestinal lesions after potassium chloride supplements: a controlled clinical trial.
The effects of a new microencapsulated potassium chloride formulation on upper gastrointestinal tract mucosa was compared with that of a popular wax-matrix formulation in 48 healthy volunteers. After a week of KCl, subjects were gastroscoped, the endoscopist being blind to the type of preparation taken. Wax-matrix formulations were associated with a higher incidence of upper gastrointestinal lesions. The lesions were not accompanied by epigastric symptoms. Glycopyrrolate, given to some volunteers to decrease gastric emptying, aggravated the effects of potassium chloride.
D000208:Acute Disease; D000328:Adult; D002986:Clinical Trials as Topic; D003692:Delayed-Action Preparations; D004357:Drug Synergism; D005753:Gastric Mucosa / Q000187:drug effects*; D005767:Gastrointestinal Diseases / Q000139:chemically induced*; D006471:Gastrointestinal Hemorrhage / Q000139:chemically induced; D006024:Glycopyrrolate / Q000009:adverse effects; D006801:Humans; D007413:Intestinal Mucosa / Q000187:drug effects*; D008297:Male; D010437:Peptic Ulcer / Q000139:chemically induced; D010439:Peptic Ulcer Perforation / Q000139:chemically induced; D011189:Potassium Chloride / Q000008:administration & dosage / Q000009:adverse effects*
D003692:Delayed-Action Preparations; D011189:Potassium Chloride; D006024:Glycopyrrolate